tiprankstipranks
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
US Market

Ultragenyx Pharmaceutical (RARE) Income Statement

Compare
796 Followers

Ultragenyx Pharmaceutical Income Statement

Last quarter (Q4 2024), Ultragenyx Pharmaceutical's total revenue was $164.88M, an increase of 29.42% from the same quarter last year. In Q4, Ultragenyx Pharmaceutical's net income was $-133.38M. See Ultragenyx Pharmaceutical’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 560.23M$ 434.25M$ 363.33M$ 351.41M$ 271.03M
Gross Profit
$ 483.50M$ 389.04M$ 335.01M$ 335.40M$ 264.90M
Operating Expenses
$ 1.02B$ 958.25M$ 983.93M$ 717.13M$ 595.02M
Depreciation and Amortization
$ 35.54M$ 26.01M$ 18.20M$ 13.24M$ 12.26M
EBITDA
$ -469.00M$ -516.45M$ -640.51M$ -410.32M$ -139.81M
Operating Income
$ -535.97M$ -569.21M$ -648.92M$ -381.74M$ -330.12M
Other Income/Expenses
$ -31.61M$ -39.26M$ -52.81M$ -71.24M$ 144.76M
Pretax Income
$ -567.59M$ -608.46M$ -701.73M$ -452.98M$ -185.36M
Net Income
$ -569.18M$ -606.64M$ -707.42M$ -454.02M$ -186.57M
Per Share Metrics
Basic EPS
$ -6.29$ -8.25$ -10.12$ -6.70$ -3.07
Diluted EPS
$ -6.29$ -8.25$ -10.12$ -6.70$ -3.07
Weighted Average Shares Outstanding
90.54M 73.54M 69.91M 67.80M 60.85M
Weighted Average Shares Outstanding (Diluted)
90.54M 73.54M 69.91M 67.80M 60.85M
Currency in USD

Ultragenyx Pharmaceutical Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis